VJHemOnc is committed to improving our service to you

VJVirtual | CD19 CARs for AML

VJHemOnc is committed to improving our service to you

Arnon Nagler

Arnon Nagler, MD, MSc, Sheba Medical Center, Tel-Aviv, Israel, discusses remission in acute myeloid leukemia (AML) with t(8; 21) following CD19-directed CAR T-cell therapy. Prof. Nagler goes on to discuss the toxicities associated with the use of CAR-T for this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter